Status:
COMPLETED
Retinal Blood Flow and Microthrombi in Type 1 Diabetes
Lead Sponsor:
Schepens Eye Research Institute
Conditions:
Diabetes
Diabetic Retinopathy
Eligibility:
All Genders
18-45 years
Phase:
PHASE2
Brief Summary
The project aims to find mechanisms for the abnormal retinal blood flow that in diabetic patients often precedes any evidence of clinical retinopathy and may contribute to the development of retinopat...
Detailed Description
The ultimate goal of this research is to contribute to the development of strategies to prevent diabetic retinopathy. This project will test the hypothesis that antiplatelet agents normalize the reduc...
Eligibility Criteria
Inclusion
- Age 18-45 years,
- type 1 diabetes duration 1-15 years,
- absent or minimal retinopathy (EDTRS 20).
- Age- and gender-matched healthy controls
Exclusion
- smoking,
- systemic diseases other than diabetes,
- retinal diseases other than diabetic retinopathy,
- pregnancy,
- bleeding disorders,
- aspirin allergy,
- use of anti-platelet agents,
- non-steroidal anti-inflammatory agents,
- angiotensin converting enzyme inhibitors,
- angiotensin receptor antagonists,
- Vitamin E in large doses.
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00406991
Start Date
June 1 2003
End Date
March 1 2006
Last Update
October 30 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schepens Eye Research Institute
Boston, Massachusetts, United States, 02114